论文部分内容阅读
目的评价聚乙二醇干扰素α-2b联合病毒唑治疗慢性丙型病毒性肝炎的临床效果及用药安全性,探讨临床慢性丙型肝炎的抗病毒方法。方法选择68例慢性丙型肝炎患者随机分成联合治疗组与对照组,联合治疗组38例,给予聚乙二醇干扰素α-2b80μg,1次/周皮下注射,加上病毒唑450mg,3次/d,疗程为6个月;对照组30例,用甘乐能干扰素α-2b3Mu隔日肌内注射1次,加上病毒唑450mg,3次/d,疗程6个月。两组停药后随访6个月。分别观察两组慢性丙肝患者治疗前后的临床症状、体征改善状况,生化应答率、病毒应答率和临床不良反应。结果治疗结束时联合治疗组显效率、有效率和总有效率分别是71.05%、18.42%和89.47%;对照组分别是66.67%、16.67%和83.34%;两组比较差异无统计学意义(P>0.05)。随访6个月联合治疗组的持续应答率为47.37%,而对照组为16.67%,两组有统计学意义(P<0.01)。两组副作用均有发热、乏力、胃肠道症状、白细胞下降、肌肉酸痛等(P>0.05)。结论聚乙二醇干扰素α-2b联合病毒唑治疗慢性丙型肝炎,可迅速缓解患者的症状体征,促进HCV-RNA的阴转,临床用安全,停药6个月后的持续完全应答显著优于甘乐能干扰素。
Objective To evaluate the clinical efficacy and safety of peginterferon alfa-2b in combination with ribavirin in the treatment of chronic hepatitis C virus (HCV), and to explore the antiviral approach to clinical chronic hepatitis C. Methods Sixty-eight patients with chronic hepatitis C were randomly divided into combined treatment group and control group. 38 patients in combination therapy group were treated with peginterferon alfa-2b80μg subcutaneously once per week, ribavirin 450mg, / d, the course of treatment was 6 months; the control group of 30 patients, intramuscular injection of ribavirin α-2b3Mu every other day once, plus ribavirin 450mg, 3 times / d, treatment for 6 months. Two groups were followed up for 6 months after withdrawal. Clinical symptoms, signs of improvement, biochemical response rate, virus response rate and clinical adverse reactions were observed before and after treatment in two groups of chronic hepatitis C patients. Results The effective rate, effective rate and total effective rate were 71.05%, 18.42% and 89.47% respectively in the combined treatment group and 66.67%, 16.67% and 83.34% in the control group respectively. There was no significant difference between the two groups (P > 0.05). The follow-up of 6 months in the combination therapy group continued response rate was 47.37%, while the control group was 16.67%, the two groups were statistically significant (P <0.01). Side effects of both groups have fever, fatigue, gastrointestinal symptoms, leukopenia, muscle soreness (P> 0.05). Conclusions Pegylated interferon alfa-2b combined with ribavirin can effectively alleviate the symptoms and signs of patients and promote the negative conversion of HCV-RNA in clinical use. The sustained complete response after 6 months of withdrawal was significant Better than Ganlenerne interferon.